GLAXOSMITHKLINE’S new chief executive, who has already made her mark with plans to divest some nutritional products, will turn next week to the main business of focusing the company’s pipeline of new drugs.
Despite her non-pharmaceutical background in consumer brands, Emma Walmsley sees improving drug research productivity as her top priority, and she wants Britain’s biggest drugmaker to have fewer but potentially more lucrative new medicine launches in future.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
